Issue 40

HMNC Brain Health on Precision Psychiatry and Psychedelics

To date, HMNC Brain Health has raised €28m in funding for the continued development of precision psychiatry. Precision psychiatry is a methodology that harnesses digital solutions to identify biological, environmental and social factors to improve patient outcomes. Opposed to a one-size-fits-all approach, HMNC Brain Health is instead developing personalised therapies with predictive diagnostics, to increase treatment efficacy and reduce treatment timeframes.

Read More

GLOBAL PSYCHEDELIC RESEARCH INSTITUTE LAUNCHED IN MELBOURNE WITH AU$40M IN FUNDING

The collaboration between university researchers plans to advance clinical studies into DMT, MDMA and psilocybin.

Read More

POLL REVEALS MAJORITY OF CANADIANS SUPPORT LEGALISATION OF PSILOCYBIN-ASSISTED THERAPY

The survey found that 82% of Canadians approve the use of psilocybin-assisted therapy for palliative care.

Read More

BUSINESS AND INVESTMENT

Havn Life harvests first flush of psilocybin mushrooms at Jamaican facility.

FDA grants PharmaTher Orphan Drug designation for ketamine treatment.

Cybin to trade on NYSE from 5 August.

Oklahoma Pain Center launches ketamine treatments.

Numinus Wellness provides quarterly update on US$63.2m cash position.

Braxia Scientific shares annual financial results.

Small Pharma provides quarterly update.

Awakn Life Sciences to open London location.

Levitee Labs acquires Earth Circle Organics.

Filament Health submits patent for psilocybin extraction.

Mindset Pharma files patent for psilocybin synthesis.

Compass Pathways appoints Guy Goodwin as Chief Medical Officer.

Mindcure appoints Jerry White as Company Advisor.

RESEARCH AND SCIENCE

Psychedelic microdosing investigated for pharmacological effect on the brain.

Could psychedelic medication be used to treat mental illness and PTSD?

Studies assessing psilocybin show improved diet, increased exercise and overall positive sense of well-being.

Usona Institute obtains research facility in Fitchburg, Wisconsin.

Psychedelics research FYI: Every clinical trial underway right now involving public and private companies.

Future space travel might require mushrooms.

REGULATION AND LEGISLATION

B.C. non-profit challenges Health Canada to end 50-year prohibition on magic mushrooms.

Psychedelics decriminalisation advancing in three more cities, spanning from coast to coast.

Partner with us